OncoMatch/Clinical Trials/NCT07032129
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
Is NCT07032129 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies BCMA/GPRC5D CAR-T cells for multiple myeloma.
Treatment: BCMA/GPRC5D CAR-T cells — This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or GPRC5D or both sequentially in the treatment of Relapsed/ Refractory Multiple myeloma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Demographics
Prior therapy
Must have received: standard treatment
Subjects with recurrent/refractory Multiple Myeloma who have failed standard treatment or lack effective treatment
Cannot have received: CAR-T cell therapy
Patients who received CAR-T therapy or other gene-modified cell therapy before screening
Cannot have received: gene-modified cell therapy
Patients who received CAR-T therapy or other gene-modified cell therapy before screening
Lab requirements
Kidney function
Creatinine ≤1.5×ULN
Liver function
Total bilirubin ≤2×ULN; ALT and AST≤2.5 x ULN; ALT and AST abnormalities due to disease, such as liver infiltration or bile duct obstruction, were determined to be less than 5×ULN. If Gilbert syndrome is diagnosed, the total bilirubin index can be relaxed to ≤3.0×ULN and the direct bilirubin ≤1.5×ULN.
Cardiac function
Electrocardiogram showed no clinically significant abnormal bands; Blood oxygen saturation >91% in non-oxygen state
Liver and kidney function, cardiopulmonary function meet the following requirements: Creatinine ≤1.5×ULN; (2) Electrocardiogram showed no clinically significant abnormal bands; Blood oxygen saturation >91% in non-oxygen state; Total bilirubin ≤2×ULN; ALT and AST≤2.5 x ULN; ALT and AST abnormalities due to disease, such as liver infiltration or bile duct obstruction, were determined to be less than 5×ULN. If Gilbert syndrome is diagnosed, the total bilirubin index can be relaxed to ≤3.0×ULN and the direct bilirubin ≤1.5×ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07032129 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, gene-modified cell therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 90 years or younger and at least 21 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages